Product Images Sevelamer Carbonate

This text is a table showing reduction in Serum Phosphorus levels over a period of time. The first column contains values from -4 to 6, the second column contains values 100, sl, Active control, Active Cont and g 807, the third column contains value Y, and the fourth column contains values 2%, 704, Fc, € 5 60, % S50, 1, 23, 29, and Sxao+ . The fifth column includes the text "§5 » £%301 sevelamer Hydrochloride” and the sixth column includes a graph showing an increase or reduction in the serum phosphorus levels. No further information is available.*

This appears to be a table or graph showing the change in phosphorus levels from baseline for patients taking Sevelamer Hydrochloride compared to an active control, over the course of a study that lasted at least 52 weeks. However, without more context or clearer formatting, it is difficult to provide more specific information.*

NDC 68382-824-27 is a package of Sevelamer Carbonate tablets containing 270 film-coated tablets. Each tablet contains 800mg sevelamer carbonate. The package insert contains dosage information. The tablets should be stored between 20°C to 25°C to maintain Controlled Room Temperature. The tablets should be kept in a tight container to protect them from moisture. This medication is manufactured by Cadila Healthcare Ltd. in Anmedabad, India and distributed by Zydus Pharmaceuticals (USA) Inc. in Penninglon, NJ.*